Novartis Pharma - רווח נקי למניה (EPS TTM) NVS

Novartis AG (NVS) maintains a stable moat through its bet on gene therapy and patent-protected innovative developments. The rolling year earnings per share (EPS) reflects this trend, where the 5.28 level captures the current state. While production robotization and AI laboratories optimize costs, geopolitical tensions and sanction risks regarding raw materials complicate logistics and the protection of rights in conflict zones.

This metric measures the real return per share by dividing total annual net income by the number of securities to assess the fundamental efficiency of the business. The net income per share trend over the last four quarters reflects the monetization of Novartis AG (NVS) unique biotechnological platforms, confirming the company's financial stability as an indispensable link in the production of innovative gene therapy.